HOME >> BIOLOGY >> NEWS
Research suggests new avenue for stopping, preventing colon cancer

NASHVILLE, Tenn. Researchers at the Vanderbilt-Ingram Cancer Center (VICC) have provided the first evidence that blocking a cellular receptor can inhibit the development of pre-cancerous colon polyps in mice.

The research suggests a new avenue for stopping or preventing colon cancer, which kills more than 50,000 Americans each year, said the paper's senior author, Raymond N. DuBois, M.D., Ph.D., Hortense B. Ingram Professor of Molecular Oncology and the VICC's associate director for Cancer Prevention and Control.

The receptor, called PPARdelta, plays an important role in development, wound healing and fat metabolism. In the current issue of the journal Cancer Cell, the scientists reported that they could inhibit polyp development in mice by "knocking out" the PPARdelta gene. PPAR stands for peroxisome proliferator-activated receptor, a family of three "transcription factors" that serve as on-off switches for a wide variety of genes.

DuBois is internationally known for his pioneering studies linking the development of colorectal cancer to the cyclooxygenase-2 (COX-2) enzyme. COX-2 is a major target for drugs that relieve the pain and inflammation of arthritis, but COX-2 gene expression is also elevated in a variety of malignancies including colorectal tumors.

COX-2 generates several potent, hormone-like substances called prostaglandins that play a role in a wide variety of physiological functions. One of them, prostaglandin E2 (PGE2), has been specifically linked to the development of colon polyps. The current study tested the effect of PGE2 in mice with the mutation that made them susceptible to polyps. Administration of the prostaglandin dramatically increased the number of intestinal polyps.

The animals were then crossed with mice without the PPARdelta gene. This generated animals with the propensity to develop colon polyps but lacking PPARdelta. When PGE2 was given to these mice, "we didn't seen any increase in polyps," DuBois said
'"/>

Contact: Cynthia Floyd Manley
cynthia.manley@vanderbilt.edu
615-936-5711
Vanderbilt University Medical Center
20-Sep-2004


Page: 1 2 3

Related biology news :

1. Researchers determine genetic cause of Timothy syndrome
2. Researchers find color sensitive atomic switch in bacteria
3. Schepens Eye Research Institute receives Roadmap grant to develop center for curing eye diseases
4. Researchers identify protein promoting vascular tumor growth
5. Researchers devise potent new tools to curb ivory poaching
6. Researchers create nanotubes that change colors, form nanocarpet and kill bacteria
7. Researchers ID chlorophyll-regulating gene
8. Environmental issues center of Inland Northwest Research Alliance 4th Annual Symposium
9. Researchers develop fast track way to discover how cells are regulated
10. Research on carbohydrate metabolism receives historical recognition
11. Researchers identify distinctive signature for metastatic prostate cancer

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/23/2017)... ARMONK, N.Y. , Aug. 23, 2017  The general public,s help ... the human microbiome—the bacteria that live in and on the human body ... ... bacteria in the human microbiome, starting with the gut. The project's goal ... in disease. Photo credit: IBM ...
(Date:6/23/2017)... ARMONK, N.Y. and ITHACA, N.Y. ... IBM ) and Cornell University, a leader in dairy ... combined with bioinformatics designed to help reduce the chances ... breaches. With the onset of this dairy project, Cornell ... the Consortium for Sequencing the Food Supply Chain, a ...
(Date:5/16/2017)... --  Bridge Patient Portal , an enterprise patient ... Systems , an electronic medical record solutions developer ... a partnership to build an interface between the ... products, including Centricity Practice Solution (CPS), Centricity Business ... integrations will allow healthcare delivery networks using GE ...
Breaking Biology News(10 mins):
(Date:10/12/2017)... FL (PRWEB) , ... October ... ... (RPS®) today announces publication of a United States multicenter, prospective clinical study ... use, disposable, point-of-care diagnostic test capable of identifying clinically significant acute bacterial ...
(Date:10/11/2017)... ... October 11, 2017 , ... The CRISPR-Cas9 ... enabling overexpression experiments and avoiding the use of exogenous expression plasmids. The simplicity ... for performing systematic gain-of-function studies. , This complement to loss-of-function studies, such ...
(Date:10/11/2017)... Netherlands and LAGUNA HILLS, Calif. ... Institute of Cancer Research, London (ICR) ... MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify patients with ... known as MUK nine . The University of ... which is partly funded by Myeloma UK, and ICR will ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights ... (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration with Children’s Hospital ...
Breaking Biology Technology:
Cached News: